Crinetics Pharmaceuticals, Inc.
CRNX
$29.24
$1.023.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 760.00K | 1.04M | 1.04M | 1.39M | 1.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 760.00K | 1.04M | 1.04M | 1.39M | 1.97M |
| Cost of Revenue | 263.06M | 240.16M | 219.17M | 201.10M | 183.40M |
| Gross Profit | -262.30M | -239.12M | -218.13M | -199.72M | -181.43M |
| SG&A Expenses | 114.44M | 99.74M | 88.64M | 78.23M | 66.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 377.49M | 339.89M | 307.81M | 279.33M | 250.13M |
| Operating Income | -376.73M | -338.85M | -306.77M | -277.95M | -248.16M |
| Income Before Tax | -328.25M | -298.41M | -277.91M | -258.54M | -235.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -328.25 | -298.41 | -277.91 | -258.54 | -235.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -328.25M | -298.41M | -277.91M | -258.54M | -235.46M |
| EBIT | -376.73M | -338.85M | -306.77M | -277.95M | -248.16M |
| EBITDA | -373.49M | -336.07M | -304.51M | -276.19M | -246.87M |
| EPS Basic | -3.82 | -3.70 | -3.72 | -3.77 | -3.77 |
| Normalized Basic EPS | -2.39 | -2.31 | -2.32 | -2.36 | -2.36 |
| EPS Diluted | -3.82 | -3.71 | -3.72 | -3.77 | -3.78 |
| Normalized Diluted EPS | -2.39 | -2.31 | -2.32 | -2.36 | -2.36 |
| Average Basic Shares Outstanding | 343.70M | 322.88M | 298.53M | 275.25M | 250.52M |
| Average Diluted Shares Outstanding | 343.70M | 322.88M | 298.53M | 275.25M | 250.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |